Telo Genomics (TELO.V) has co-written and published an academic study regarding their ability to positively identify high-risk versus low-risk smouldering myeloma patients in a longitudinal multiple myeloma clinical study…
TELO.V
Telo Genomics (TELO.V) was granted three of its pending patent applications today, according to a press release. The company already has patents pertaining to hematological cancers in the United…